The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
MINNEAPOLIS, March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia (CML) patients. The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy. CML patients must undergo regular monitoring to ensure that they continue to receive the most appropriate treatment for their cancer. The QuantideX kit allows for direct reporting on the International Scale and further streamlines the workflow with easy-to-use analysis software. Clinical lab scientists can run up to 49 samples per plate for a scalable solution.
"Bio-Techne is dedicated to quality and compliance, and we applaud this new IVDR for strengthening the safety and performance requirements for diagnostic products," said Matt McManus, President of Bio-Techne's Diagnostics & Genomics Segment. "We are proud to achieve this new certification and will continue to provide the molecular diagnostic and liquid biopsy solutions that deliver world-class performance, scalability, and reliable results for the laboratory scientists, physicians, and patients who count on us."
This is a bit more interesting for when production starts.
Gemfields is pleased to announce the results of an auction comprised of commercial quality rough emeralds held during the period 5 - 22 March 2024.
Highlights: March 2024 - Commercial Quality Emerald Auction
· Total auction revenues of USD 17.1 million
· 43 lots were offered for sale, of which 40 were sold (93%)
· Average price of USD 4.45 per carat
· The 47 auctions of Kagem gemstones held since July 2009 have generated USD 1,006 million in total revenues, reaching the USD 1 billion mark
Thousands of lives could be saved from lung cancer if screening programmes for the disease were introduced in Scotland, Wales and Northern Ireland, according to new research from Cancer Research UK (CRUK).
Lung cancer is the leading cause of cancer death across the four countries of the UK. So far, England is the country implementing the UK National Screening Committee’s recommendation to offer lung cancer screening to all those at the highest risk of the disease (people aged between 55 and 74 who either smoke or used to smoke). It plans to reach 40% of this group by March 2025 and 100% by March 2030.
The targeted lung checks being introduced in England aim to help diagnose lung cancers earlier when they are more treatable.
The latest calculations suggest equivalent lung cancer screening programmes could diagnose around 4,000 more lung cancer patients in Scotland at an early stage (stage 1 or 2) over the next decade, as well as 2,400 more people in Wales and 1,400 in Northern Ireland.
We strongly advocate early lung cancer screening initiatives, and we are developing a simple blood test for a biomarker called CIZ1B that is found in early-stage lung cancer patients. With more early-stage cancer detection methods available, more lives can be saved.
CIZ need to get a shift on
Blood test reveals best lung cancer treatment https://www.bbc.co.uk/news/health-68624334
Starting to get interesting. If buying keeps up it could get back above 3p going into April.
But I think there’s a good chance of a sell off. Drawdown still in back of the mind. Hope it’s not just a Hopium pump to get the drawdown done and flipped.
Bear in mind a lot of buyers came in between 3p and 4.5p so they might look for an exit when they breakeven.
Just thoughts.
Be interested in Widglides view ? Bring the mood down
Re - cancers. From the pending patent application
0167) As used herein, the term "cancer" or "cancerous" refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. The term is meant to include all types of cancerous growths or oncogenic processes, meta- static tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. The term "cancer" includes malignancies of
the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, reproductive and genito-urinary tract, as well as adenocar- cinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicu- lar tumours, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
(0168] Suitably, the cancer may be lung cancer, lym- phoma, kidney cancer, breast cancer, liver cancer, bladder cancer, ovarian or thyroid cancer.
[0169] In one embodiment, the cancer is lung cancer. The Lung cancer may be small cell lung cancer. The lung cancer may be non-small cell lung cancer.
Fast food from the RNS
This agreement represents a significant opportunity to bring early and cost-effective cancer detection to the people of China. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about GBP100 per test, the total available market for tests based on the CIZ1B biomarker would be GBP3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion).
Just a reminder regarding warrant strike prices
On 14 May 2021 the Company issued investor warrants to subscribe for 11,000,000 Ordinary Shares at a fixed price of 15p per share valid for three years until 13 May 2024.
On 14 May 2021 the Company issued broker and adviser warrants to subscribe for 1,350,000 Ordinary Shares at a fixed price of 10p per share valid for three years until 13 May 2024. 250,000 of these broker warrants are automatically exercisable upon the Company's share price equalling 20p per share. The fair value of these warrants at 31 December 2021 was GBP36,000 and has been accounted for as a cost to the Company and a reduction of the share premium account ( see statement of changes in equity on pages 42 to 43).
I know it’s a sideshow but it’s a bit of positive news which will hopefully see an increase in Put option value as CDT make progress. (Yes I know too if CIZ haven’t sold them at a massive loss etc etc 😜)
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in identifying drugs that can be applied across multiple disease states, combining research and commercial skills to advance drugs to market, and working with premier scientific thought leaders. She has a specific focus in solid-form technology and its associated intellectual property, having held leadership positions at publicly traded companies in this space, as well as consulting roles for several pharmaceutical companies on all matters relating to solid-form technology. She has successfully shepherded multiple solid-form candidates from discovery stage into the clinic, and is the author of over 50 solid-form intellectual property patents. Dr. Holland earned a PhD in chemistry from the University of Leeds, UK, which was sponsored by Pfizer, Inc., before starting her career at companies including Millennium Pharmaceuticals and Stylacats Limited.
In addition, Conduit has engaged Dr. Jeff Lindeman to consult on intellectual property strategies as part of the Company’s research and development of its solid-form candidates. An international speaker, Dr. Lindeman has authored book chapters on patent strategies relating to pharmaceutical solid-state forms. Prior to opening his consulting firm Two Notch Solutions, LLC, in 2009, Dr. Lindeman founded and then successfully sold J.A. Lindeman & Co. PLLC (now Raphael Bellum PLLC) and has over 30 years of intellectual property law experience, including as an adjunct patent law professor at American University and as a United States patent examiner. His role with the Company is as a consultant, not legal counsel.
“The appointment of Jo as Chief Scientific Officer underscores Conduit’s commitment to optimizing the value of our current intellectual property assets, while concurrently fostering the creation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer. “Jo and Jeff have over 20 years of experience working together, and their new leadership roles will significantly enhance our intellectual property state, strategically positioning Conduit for future out-licensing opportunities.”